Business
Crescita Therapeutics(TM) Reports Positive Topline Results of Phase 2 Clinical Trial for the Treatment of Plaque Psoriasis
Crescita Therapeutics™ Reports Positive Topline Results of Phase 2 Clinical Trial f...
About this update from Crescita Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\nCrescita Therapeutics™ Reports Positive Topline Results of Phase 2 Clinical Trial for the Treatment of Plaque Psoriasis\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nMISSISSAUGA, ON, Sept. 18, 2017\n\n\n\nMISSISSAUGA, ON, Sept. 18, 2017 /CNW/ - Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products today announced that it has received positive topline results from a Phase 2 clinical trial (the Trial) in patients with plaque psoriasis (MiCal 1) conducted by its partner, Ferndale Laboratories, Inc. (Ferndale), in conjunction with a leading U.S. Contract Research Organization (CRO).  The Trial demonstrated statistical significance in the achievement of its primary endpoint. \n\n\n \n \n\n \nMiCal 1 is the first of two dermatological products being developed in collaboration with our partner.  Under the terms of the collaboration, Crescita utilized its proprietary Multiplexed Molecular Penetration Enhancer Technology (MMPE™) to formulate two patented topical dermatology product candidates. It is anticipated that the product candidates will be made available for out-licensing at or before the completion of development. Licensing revenues would be shared between the parties, where Crescita's share would reflect its contribution of the patented formulations.    \n\n\"We are excited by the positive results of this Phase 2 trial which studied the first developed formulation,\" said Serge Verreault, Crescita's President. \"We believe that MiCal 1 can have a clinically meaningful benefit for the treatment of patients suffering from moderate to severe plaque psoriasis.\"\n\nThe TrialThe multi-centre, randomized, vehicle-controlled, double-blind, parallel group Phase 2 trial was conducted to determine and compare the efficacy and safety of MiCal 1 in the treatment of moderate to severe plaque psoriasis. The Trial was conducted at multiple U.S. study sites and enrolled 89 patients.&...